Linagliptin Empagliflozin Metformin Extended-Release Tablets 5/2.5/1000 mg
Empagliflozin 5mg · Linagliptin Micronized 2.5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
MFDS item code 202502780 · Approved 2025.10.28
Improvement of glycemic control in type 2 diabetes mellitus
This medication effectively aids blood sugar control in patients with type 2 diabetes through the combined action of three components: empagliflozin, linagliptin, and metformin. Used in conjunction with diet and exercise, it significantly helps manage blood sugar. This medication lowers blood sugar and contributes to reducing the risk of diabetes complications through its composite actions. Therefore, it is used to improve blood sugar control in patients with type 2 diabetes.
In antidiabetic therapy, the dose of this medication should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum daily doses of each component: empagliflozin 25mg, linagliptin 5mg, and extended-release metformin hydrochloride 2000mg. To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, this medication should be taken once daily with the evening meal. If the dose of metformin hydrochloride needs to be adjusted, the dose should be titrated gradually. Patients taking this medication as 10/5/1000mg or 25/5/1000mg extended-release tablets should take 1 tablet once daily. Patients taking this medication as 5/2.5/1000mg or 12.5/2.5/1000mg extended-release tablets should take 2 tablets once daily. If additional glycemic control is needed in patients who tolerate the recommended starting dose of this medication—empagliflozin 10mg/linagliptin 5mg/metformin hydrochloride 1000mg once daily—the dose of empagliflozin or metformin may be increased. Patients switching from combination therapy with empagliflozin, linagliptin, and metformin hydrochloride to this medication should receive the same doses they were previously taking. The safety and efficacy of this medication have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because such a change may lead to changes in glycemic control, any changes in treatment for patients with type 2 diabetes should be made under close monitoring. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. To maintain its extended-release properties, this medication should be swallowed whole and not split, crushed, ground, or chewed. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medication may be used by adjusting the dose of metformin hydrochloride, one of its components, if it is well tolerated and the patient does not have other conditions that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this medication should be discontinued immediately. Renal function should be assessed every 3~6 months.
This medication may cause a rare side effect called severe lactic acidosis, which can lead to death. Therefore, it should not be used in certain patients, for instance, those with an allergy to the components of this medication or those with type 1 diabetes, patients undergoing dialysis, or patients with severe renal impairment. Additionally, it should be avoided or used cautiously in patients with acute infections, dehydration, congestive heart failure, or those scheduled for surgery, as these conditions may destabilize the body. Dosage adjustments are necessary based on renal function, and patients with impaired renal function should undergo regular blood tests to monitor renal status. Patients with heart failure or a history of pancreatitis require special caution when using this medication, and should immediately discontinue use if symptoms of acute pancreatitis occur. This medication can cause hypoglycemia; therefore, when used together with insulin or other hypoglycemic agents, dosage adjustments are necessary to reduce the risk of hypoglycemia. During treatment, irregular meals, vigorous exercise, or concurrent use of certain drugs can increase the risk of hypoglycemia and lactic acidosis, hence caution is advisable. This medication contains the dye Yellow No. 4, requiring careful use in patients allergic to this component. Major side effects include urinary tract infections, genital infections, hypoglycemia, pancreatitis, skin rashes, among others, and it is vital to consult a physician immediately if any abnormal symptoms arise. Especially in elderly patients or those at risk of fluid loss, caution regarding dehydration or hypotension is necessary, and regular blood pressure and blood tests are recommended. This medication should also be used with caution in patients with impaired liver function, and excessive alcohol consumption should be avoided. Moreover, while taking this medication, serious infections such as urinary tract infections or perineal necrosis may occur, so prompt notification to medical staff is essential if related symptoms appear. A skin condition known as blistering dermatitis herpetiformis may develop; hence, if blisters or rashes appear on the skin, immediate discontinuation and consultation with a specialist is advised. This medication should be taken whole without crushing or chewing the tablets, although the shell of the medication may be excreted in the stool, which is normal. Caution is also needed while driving or operating machinery due to the risk of hypoglycemia, especially when used alongside insulin. Finally, this medication may interact with other medications; therefore, if you are taking any other medicine, be sure to inform your doctor or pharmacist.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is advisable to maintain storage temperature between 1 and 30 degrees Celsius at room temperature.
White and light green, bilaterally convex, oval-shaped film-coated tablets
Bottle packaging - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 5mg · Linagliptin Micronized 2.5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Empagliflozin 10mg · Linagliptin Micronized 5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Empagliflozin 12.5mg · Linagliptin Micronized 2.5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Empagliflozin 25mg · Linagliptin Micronized 5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.